News | February 12, 2015

ACC, Symphony Health Solutions Create New Cardiac Research Platform

Platform contains medical history of 5 million anonymized patients

February 12, 2015 – Symphony Health Solutions (SHS) and the American College of Cardiology announced the completion of a new research platform. The HIPAA-compliant platform combines anonymized patient-level data from the ACC's National Cardiovascular Data Registry (NCDR) with SHS's Integrated Dataverse, which includes prescription, medical and hospital claims. The newly integrated data includes approximately 5 million anonymized patients with up to six years of observed diagnoses, procedures, therapies and related findings.

Information from a large set of patients that is both broad in scope and deep in detail has, before now, been difficult to obtain — yet vital to improve care. The creation of a new analytical platform now enables a wide range of new analyses to help achieve that goal. The organizations will use the combined data sources to complete research projects focused on clinical outcomes, comparative effectiveness, therapy adoption and use, and population health, as well as additional studies and projects of interest. These analyses of patterns and treatments can ultimately improve care, enhance outcomes and reduce unnecessary healthcare costs.

"This analytic platform is ground-breaking in the level of data it will provide," said John S. Rumsfeld, M.D., Ph.D., FACC, chief science officer of the American College of Cardiology National Cardiovascular Data Registries. "The partnership between ACC and SHS brings together the detailed clinical data from the registries with the longitudinal data resources of SHS. This creates a synergy that can yield critical insights on improving cardiovascular care and patient outcomes."

Analytics solutions produced through the collaboration will have broad applicability across the healthcare market. Entities such as life sciences organizations and the government, with whom ACC and SHS engage today, will also benefit from the new research offerings.

For more information: www.symphonyhealth.com or www.acc.org


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now